Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate to severe hidradenitis suppurativa
Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP)
An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - Nintedanib in PF-ILD (extension)
100 Clinical Results associated with SCS Boehringer Ingelheim Comm.V
0 Patents (Medical) associated with SCS Boehringer Ingelheim Comm.V
100 Deals associated with SCS Boehringer Ingelheim Comm.V
100 Translational Medicine associated with SCS Boehringer Ingelheim Comm.V